Jaguar8 commented on a stock · Oct 8, 2024 20:05

NEWS

NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

NKGen Biotech Inc. (Nasdaq: NKGN) announced upcoming poster presentations at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) in Madrid, Spain from October 29 – November 1, 2024. The presentations will cover:
1. A final report of a Phase 1 dose escalation study and a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study of troculeucel in Alzheimer's disease subjects.
2. Further biomarker analysis and implications for use in prevention of Alzheimer's disease using non-genetically modified natural killer cells (SNK01) with enhanced activity.
The posters will be presented during Poster Session 1 on October 29-30, 2024. Full abstracts will be included in the special CTAD edition of the Journal of Prevention of Alzheimer's Disease (JPAD).

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

9245 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8162

Followers

Following

93K

Visitors